U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H45NO5S
Molecular Weight 507.7278
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEFAMULIN

SMILES

C=C[C@]1(C)C[C@]([H])([C@]2(C)C([H])(C)CC[C@]3(CCC(=O)[C@@]23[H])[C@@]([H])(C)[C@]1([H])O)OC(=O)CS[C@]4([H])CC[C@]([H])(C[C@@]4([H])O)N

InChI

InChIKey=KPVIXBKIJXZQJX-CSOZIWFHSA-N
InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16?,17-,18+,20+,21+,22+,24-,25-,26+,27-,28-/m0/s1

HIDE SMILES / InChI
LEFAMULIN is a pleuromutilin antibiotic under development for the treatment of community-acquired bacterial pneumonia, as well as acute bacterial skin and skin structure infections. It inhibits bacterial protein synthesis by binding to the peptidyl transferase center of the 50S ribosome, resulting in the cessation of bacterial growth.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.5 μg/mL
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.6 μg/mL
150 mg 2 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2.24 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.24 μg/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27 μg × h/mL
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
28.6 μg × h/mL
150 mg 2 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
30.7 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
32.7 μg × h/mL
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
150 mg single, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8 h
150 mg 2 times / day steady-state, intravenous
dose: 150 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
8 h
600 mg 2 times / day steady-state, oral
dose: 600 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LEFAMULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
200 mg 2 times / day multiple, intravenous
Highest studied dose
Dose: 200 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
healthy, adults
400 mg single, intravenous
Highest studied dose
healthy, adults
600 mg 2 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
healthy, adults
750 mg single, oral
Highest studied dose
healthy, adults
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Other AEs: Diarrhea, Nausea...
Other AEs:
Diarrhea (12%)
Nausea (5%)
Vomiting (3%)
Alanine aminotransferase increased (2%)
Aspartate aminotransferase increased (2%)
Liver function test increased (2%)
Anemia (<2%)
Thrombocytopenia (<2%)
Atrial fibrillation (<2%)
Palpitations (<2%)
Abdominal pain (<2%)
Constipation (<2%)
Dyspepsia (<2%)
Epigastric discomfort (<2%)
Gastritis erosive (<2%)
Clostridium difficile colitis (<2%)
Oropharyngeal candidiasis (<2%)
Vulvovaginal candidiasis (<2%)
Somnolence (<2%)
Urinary retention (<2%)
Anxiety (<2%)
Diarrhea (12%)
Nausea (5%)
Vomiting (3%)
Alanine aminotransferase increased (2%)
Aspartate aminotransferase increased (2%)
Liver function test increased (2%)
Anemia (<2%)
Thrombocytopenia (<2%)
Atrial fibrillation (<2%)
Palpitations (<2%)
Abdominal pain (<2%)
Constipation (<2%)
Dyspepsia (<2%)
Epigastric discomfort (<2%)
Gastritis erosive (<2%)
Clostridium difficile colitis (<2%)
Oropharyngeal candidiasis (<2%)
Vulvovaginal candidiasis (<2%)
Somnolence (<2%)
Urinary retention (<2%)
Anxiety (<2%)
Sources:
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Other AEs: Infusion site pain, Infusion site phlebitis...
Other AEs:
Infusion site pain (7%)
Infusion site phlebitis (7%)
Injection site reaction (7%)
Alanine aminotransferase increased (3%)
Aspartate aminotransferase increased (3%)
Liver function test increased (3%)
Nausea (3%)
Hypokalemia (3%)
Insomnia (3%)
Headache (2%)
Anemia (<2%)
Thrombocytopenia (<2%)
Atrial fibrillation (<2%)
Palpitations (<2%)
Abdominal pain (<2%)
Constipation (<2%)
Dyspepsia (<2%)
Epigastric discomfort (<2%)
Gastritis erosive (<2%)
Clostridium difficile colitis (<2%)
Oropharyngeal candidiasis (<2%)
Vulvovaginal candidiasis (<2%)
Somnolence (<2%)
Urinary retention (<2%)
Anxiety (<2%)
Infusion site pain (7%)
Infusion site phlebitis (7%)
Injection site reaction (7%)
Alanine aminotransferase increased (3%)
Aspartate aminotransferase increased (3%)
Liver function test increased (3%)
Nausea (3%)
Hypokalemia (3%)
Insomnia (3%)
Headache (2%)
Anemia (<2%)
Thrombocytopenia (<2%)
Atrial fibrillation (<2%)
Palpitations (<2%)
Abdominal pain (<2%)
Constipation (<2%)
Dyspepsia (<2%)
Epigastric discomfort (<2%)
Gastritis erosive (<2%)
Clostridium difficile colitis (<2%)
Oropharyngeal candidiasis (<2%)
Vulvovaginal candidiasis (<2%)
Somnolence (<2%)
Urinary retention (<2%)
Anxiety (<2%)
Sources:
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Disc. AE: Infectious pleural effusion, Lung abscess...
Other AEs: Infectious pleural effusion, Lung abscess...
AEs leading to
discontinuation/dose reduction:
Infectious pleural effusion (1 patient)
Lung abscess (1 patient)
Pneumonia (1 patient)
Pulmonary tuberculosis (1 patient)
Acute respiratory distress syndrome (1 patient)
Acute respiratory failure (1 patient)
Chronic obstructive pulmonary disease (1 patient)
Pulmonary edema (1 patient)
Vomiting (2 patients)
Abdominal pain upper (1 patient)
Infusion site phlebitis (1 patient)
Injection site reaction (1 patient)
Hepatitis toxic (1 patient)
Other AEs:
Infectious pleural effusion (1 patient)
Lung abscess (1 patient)
Pneumonia (1 patient)
Pulmonary tuberculosis (1 patient)
Acute respiratory distress syndrome (1 patient)
Acute respiratory failure (1 patient)
Chronic obstructive pulmonary disease (1 patient)
Pulmonary edema (1 patient)
Vomiting (2 patients)
Abdominal pain upper (1 patient)
Infusion site phlebitis (1 patient)
Injection site reaction (1 patient)
Hepatitis toxic (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 12%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Diarrhea 12%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Alanine aminotransferase increased 2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Alanine aminotransferase increased 2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Aspartate aminotransferase increased 2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Aspartate aminotransferase increased 2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Liver function test increased 2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Liver function test increased 2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Vomiting 3%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Vomiting 3%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Nausea 5%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Nausea 5%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Abdominal pain <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Abdominal pain <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Anemia <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Anemia <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Anxiety <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Anxiety <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Atrial fibrillation <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Atrial fibrillation <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Clostridium difficile colitis <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Clostridium difficile colitis <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Constipation <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Constipation <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Dyspepsia <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Dyspepsia <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Epigastric discomfort <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Epigastric discomfort <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Gastritis erosive <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Gastritis erosive <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Oropharyngeal candidiasis <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Oropharyngeal candidiasis <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Palpitations <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Palpitations <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Somnolence <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Somnolence <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Thrombocytopenia <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Thrombocytopenia <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Urinary retention <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Urinary retention <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Vulvovaginal candidiasis <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Vulvovaginal candidiasis <2%
600 mg 2 times / day multiple, oral
Recommended
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, adults
n = 368
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 368
Sources:
Headache 2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Headache 2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Alanine aminotransferase increased 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Alanine aminotransferase increased 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Aspartate aminotransferase increased 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Aspartate aminotransferase increased 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Hypokalemia 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Hypokalemia 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Insomnia 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Insomnia 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Liver function test increased 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Liver function test increased 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Nausea 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Nausea 3%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infusion site pain 7%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infusion site pain 7%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infusion site phlebitis 7%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infusion site phlebitis 7%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Injection site reaction 7%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Injection site reaction 7%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Abdominal pain <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Abdominal pain <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Anemia <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Anemia <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Anxiety <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Anxiety <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Atrial fibrillation <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Atrial fibrillation <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Clostridium difficile colitis <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Clostridium difficile colitis <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Constipation <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Constipation <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Dyspepsia <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Dyspepsia <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Epigastric discomfort <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Epigastric discomfort <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Gastritis erosive <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Gastritis erosive <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Oropharyngeal candidiasis <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Oropharyngeal candidiasis <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Palpitations <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Palpitations <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Somnolence <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Somnolence <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Thrombocytopenia <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Thrombocytopenia <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Urinary retention <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Urinary retention <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Vulvovaginal candidiasis <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Vulvovaginal candidiasis <2%
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Abdominal pain upper 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Acute respiratory distress syndrome 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Acute respiratory failure 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Chronic obstructive pulmonary disease 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Hepatitis toxic 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infectious pleural effusion 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infusion site phlebitis 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Injection site reaction 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Lung abscess 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Pneumonia 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Pulmonary edema 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Pulmonary tuberculosis 1 patient
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Abdominal pain upper 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Acute respiratory distress syndrome 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Acute respiratory failure 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Chronic obstructive pulmonary disease 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Hepatitis toxic 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infectious pleural effusion 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Infusion site phlebitis 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Injection site reaction 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Lung abscess 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Pneumonia 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Pulmonary edema 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Pulmonary tuberculosis 1 patient
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Vomiting 2 patients
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
Vomiting 2 patients
Disc. AE
150 | 600 mg|mg 2 | 2 times / day|day multiple|multiple, intravenous|oral (complex)
Recommended
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Route: intravenous|oral
Route: multiple|multiple
Dose: 150 | 600 mg|mg, 2 | 2 times / day|day
Sources:
unhealthy, adults
n = 273
Health Status: unhealthy
Condition: community-acquired bacterial pneumonia (CABP)
Age Group: adults
Sex: M+F
Population Size: 273
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 24.5 uM]
no [IC50 41 uM]
no [IC50 >122 uM]
no [IC50 >122 uM]
no [IC50 >122 uM]
no [IC50 >200 uM]
no [IC50 >200 uM]
no [IC50 >200 uM]
no [IC50 >200 uM]
no [IC50 >200 uM]
no
no
no
no
no
weak [IC50 122 uM]
weak [IC50 122 uM]
weak [IC50 13.76 uM]
yes [IC50 0.297 uM]
yes [IC50 42.2 uM]
yes [IC50 76.4 uM]
yes [Ki 0.86 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
yes
yes
yes
yes (co-administration study)
Comment: increased the arithmetic mean Cmax and AUC0-inf of LEF by 58% and 165%, respectively, when administered with ketoconazole (strong inhibitor); reduced the arithmetic mean Cmax and AUC0-inf of LEF by 57% and 72%, respectively, when administered with rifampin (strong inducer)
Page: 126;269;270
Tox targets
PubMed

PubMed

TitleDatePubMed
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.
2016 Apr
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.
2016 Jul
Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
2018 Sep
Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
2019 Jan

Sample Use Guides

Lefamulin was evaluated against various Streptococcus pneumoniae serotypes that were collected from adults with lower respiratory tract infections. Lefamulin exhibited MIC50 and MIC90 values of 0.12 and 0.25 μg/ml, respectively, against the entire collection (n = 822). Similar results were obtained for lefamulin against each of the most common serotypes as well as against multidrug-resistant isolates and strains that are nonsusceptible to ceftriaxone or erythromycin.
Name Type Language
LEFAMULIN
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
LEFAMULIN [USAN]
Common Name English
ACETIC ACID, 2-(((1R,2R,4R)-4-AMINO-2-HYDROXYCYCLOHEXYL)THIO)-, (3AS,4R,5S,6S,8R,9R,9AR,10R)-6-ETHENYLDECAHYDRO-5-HYDROXY-4,6,9,10-TETRAMETHYL-1-OXO-3A,9-PROPANO-3AH-CYCLOPENTACYCLOOCTEN-8-YL ESTER
Systematic Name English
LEFAMULIN [WHO-DD]
Common Name English
(+)-LEFAMULIN
Common Name English
BC-3781
Code English
LEFAMULIN [INN]
Common Name English
Code System Code Type Description
RXCUI
2198944
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL3291398
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
INN
9849
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
LACTMED
Lefamulin
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
DRUG CENTRAL
5348
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
FDA UNII
21904A5386
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
NCI_THESAURUS
C166531
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
DRUG BANK
DB12825
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
CAS
1061337-51-6
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY
PUBCHEM
58076382
Created by admin on Fri Jun 25 20:40:16 UTC 2021 , Edited by admin on Fri Jun 25 20:40:16 UTC 2021
PRIMARY